Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Catalent, Inc.CTLT · Entity 16279 | Director | October 27, 2023 | October 31, 2023 |
| Quanterix CorpQTRX · Entity 6649 | Director | January 02, 2026 | January 06, 2026 |
| Societal CDMO, Inc.REPH · Entity 92137 | Director | December 05, 2019 | December 17, 2019 |
| Sotera Health CoSHC · Entity 3869 | Director | May 22, 2026 | May 27, 2026 |
| Stevanato Group S.p.A.STVN · Entity 3826 | Director | June 12, 2026 | June 26, 2026 |
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Sr VP & Chief Commercial Offic | February 19, 2019 | February 22, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Catalent, Inc.
Report date October 27, 2023 · Filed October 31, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,339 |
Reported balance
After 2023-10-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-10-27 · Grant · Acquired 6,993 · Balance 24,339 F1: The equity acquired by the reporting person is the annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award, subject to continued service. F2: Includes restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The equity acquired by the reporting person is the annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award, subject to continued service.
F2: Includes restricted stock units.
Quanterix Corp
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 57,212 |
Reported balance
After 2026-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 23,372 · Balance 57,212 F1: Represents restricted stock units that vest as to 100% of the shares on January 2, 2027 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2: Includes 35,216 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest as to 100% of the shares on January 2, 2027 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock.
F2: Includes 35,216 restricted stock units.
Societal CDMO, Inc.
Report date December 05, 2019 · Filed December 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,283 |
Reported balance
After 2019-12-05 transaction · row 1
1 source rowRow 1 · 2019-12-05 · Grant · Acquired 11,071 · Balance 39,283 F1: These restricted stock units will vest in full on the earlier of (i) a change of control of Recro Pharma, Inc. (the "Company") (as defined in the Company's 2018 Amended and Restated Equity Incentive Plan) or (ii) December 5, 2020, subject to continued service with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units will vest in full on the earlier of (i) a change of control of Recro Pharma, Inc. (the "Company") (as defined in the Company's 2018 Amended and Restated Equity Incentive Plan) or (ii) December 5, 2020, subject to continued service with the Company.
Sotera Health Co
Report date May 22, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par value per share ("Common Stock")SEC Table I · non-derivative | Direct | 54,191 |
Reported balance
After 2026-05-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-22 · Grant · Acquired 14,970 · Balance 54,191 F1: These securities consist of 14,970 restricted stock units ("RSUs") that were granted on May 22, 2026, pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incenctive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs will vest in full on the earlier of (i) the first anniversary of the date of grant, or (ii) the date immediately prior to the Issuer's next regular annual shareholders meeting, subject to the Reporting Person's continued service as a non-employee director of the Issuer through such date. F2: These securities consist of 14,970 RSUs and 39,221 shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities consist of 14,970 restricted stock units ("RSUs") that were granted on May 22, 2026, pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incenctive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs will vest in full on the earlier of (i) the first anniversary of the date of grant, or (ii) the date immediately prior to the Issuer's next regular annual shareholders meeting, subject to the Reporting Person's continued service as a non-employee director of the Issuer through such date.
F2: These securities consist of 14,970 RSUs and 39,221 shares of Common Stock.
Stevanato Group S.p.A.
Report date June 12, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 5,757 |
Ending reported balance
After 2026-06-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-12 · Grant · Acquired 4,975 · Balance 7,250 F1: Represents ordinary shares granted as equity compensation in connection with the Reporting Person's service as director. Row 2 · 2026-06-15 · Sale · Disposed 1,493 · Balance 5,757 F2: Represents ordinary shares sold by the Reporting Person to cover tax obligations associated with the grant of ordinary shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents ordinary shares granted as equity compensation in connection with the Reporting Person's service as director.
F2: Represents ordinary shares sold by the Reporting Person to cover tax obligations associated with the grant of ordinary shares.
WEST PHARMACEUTICAL SERVICES INC
Report date February 19, 2019 · Filed February 22, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,692.1476 |
Reported balance
After 2019-02-19 transaction · row 1
1 source rowRow 1 · 2019-02-19 · Grant · Acquired 2,099 · Balance 23,692.1476 F1: 2016 PSUs (PP15) award vesting. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.51 · Expires 2029-02-19 | Direct | 14,280 |
Reported balance
After 2019-02-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-19 · Grant · Acquired 14,280 · Balance 14,280 F2: This award vests in four equal annual installments beginning on February 19, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: 2016 PSUs (PP15) award vesting.
F2: This award vests in four equal annual installments beginning on February 19, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 26, 2026 10:05 UTC | Stevanato Group S.p.A. STVN · Entity 3826 | SaleOrdinary Shares | 1,493 | $17.09 | $25,515.37 |
DisclosureSEC source: 0001193125-26-283788 · ownership.xml · nonDerivative · entry 2 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,757 F2 · shares: Represents ordinary shares sold by the Reporting Person to cover tax obligations associated with the grant of ordinary shares. Read SEC document |
| June 12, 2026 Filed Jun 26, 2026 10:05 UTC | Stevanato Group S.p.A. STVN · Entity 3826 | GrantOrdinary Shares | 4,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-283788 · ownership.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,250 F1 · shares: Represents ordinary shares granted as equity compensation in connection with the Reporting Person's service as director. Read SEC document |
| May 22, 2026 Filed May 27, 2026 21:36 UTC | Sotera Health Co SHC · Entity 3869 | GrantCommon Stock, $0.01 par value per share ("Common Stock") | 14,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-242231 · ownership.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,191 F1 · shares: These securities consist of 14,970 restricted stock units ("RSUs") that were granted on May 22, 2026, pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incenctive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs will vest in full on the earlier of (i) the first anniversary of the date of grant, or (ii) the date immediately prior to the Issuer's next regular annual shareholders meeting, subject to the Reporting Person's continued service as a non-employee director of the Issuer through such date. F2 · balance_after: These securities consist of 14,970 RSUs and 39,221 shares of Common Stock. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:45 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 23,372 | $0.00 | $0.00 |
DisclosureSEC source: 0001553599-26-000001 · primarydocument.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,212 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on January 2, 2027 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 35,216 restricted stock units. Read SEC document |
| May 22, 2025 Filed May 27, 2025 20:49 UTC | Sotera Health Co SHC · Entity 3869 | GrantCommon Stock, $0.01 par value per share ("Common Stock") | 19,132 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-077814 · ownership.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,221 F1 · shares: These securities consist of 19,132 restricted stock units ("RSUs") that were granted on May 22, 2025, pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incentive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs will vest in full on the earlier of (i) the first anniversary of the date of grant, or (ii) the date immediately prior to the Issuer's next regular annual shareholders meeting, subject to the Reporting Person's continued service as a non-employee director of the Issuer through such date. F2 · balance_after: These securities consist of 19,132 RSUs and 20,089 shares of Common Stock. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:48 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (Right to Buy) · Derivative | 15,821 | $0.00 Strike: $10.76 | $0.00 |
DisclosureSEC source: 0001562180-25-000202 · primarydocument.xml · derivative · entry 2 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,821 Underlying: Common Stock · 15,821 shares Expires 2035-01-02 F3 · shares: Represents non-qualified stock option to purchase 15,821 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:48 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 7,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000202 · primarydocument.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,840 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2025 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 11,844 restricted stock units. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:55 UTC | Sotera Health Co SHC · Entity 3869 | GrantCommon Stock, $0.01 par value per share ("Common Stock") | 20,089 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-066037 · ownership.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,089 F1 · shares: These securities consist of 20,089 Restricted Stock Units ("RSUs") that were granted on May 24, 2024, pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incentive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs will vest in full on the earlier of (i) the first anniversary of the date of grant, or (ii) the date immediately prior to the Issuer's next regular annual shareholders meeting, subject to the Reporting Person's continued service as a non-employee director of the Issuer through such date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:09 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (Right to Buy) · Derivative | 6,412 | $0.00 Strike: $27.15 | $0.00 |
DisclosureSEC source: 0001562180-24-000232 · primarydocument.xml · derivative · entry 2 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,412 Underlying: Common Stock · 6,412 shares Expires 2034-01-02 F3 · shares: Represents non-qualified stock option to purchase 6,412 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:09 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 2,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000232 · primarydocument.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,405 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2024 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 11,765 restricted stock units. Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 21:00 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 6,993 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-23-000153 · wk-form4_1698786044.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,339 F1 · shares: The equity acquired by the reporting person is the annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award, subject to continued service. F2 · balance_after: Includes restricted stock units. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:03 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (Right to Buy) · Derivative | 12,124 | $0.00 Strike: $12.86 | $0.00 |
DisclosureSEC source: 0001562180-23-000102 · primarydocument.xml · derivative · entry 3 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,124 Underlying: Common Stock · 12,124 shares Expires 2033-01-03 F5 · shares: Represents non-qualified stock option to purchase 12,124 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated 2018 Non-Employee Director Compensation Policy. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:03 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 918 | $12.86 | $11,805.48 |
DisclosureSEC source: 0001562180-23-000102 · primarydocument.xml · nonDerivative · entry 2 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,458 F3 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the fourth quarter of 2022. F4 · price: Closing price of the Company's common stock on the Nasdaq Global Market on January 3, 2023. F2 · balance_after: Includes 21,310 restricted stock units. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:03 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 8,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000102 · primarydocument.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,540 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2023 granted pursuant to the Quanterix Corporation Amended and Restated 2018 Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 21,310 restricted stock units. Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 20:49 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 4,149 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-22-000169 · wf-form4_166724935268364.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,346 F1 · kind: The equity acquired by the reporting person is the regular, annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation package. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur on the earlier of one year from the date of award and the date of the Issuer's fiscal 2023 annual meeting of shareholders. F2 · balance_after: Includes restricted stock units. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:04 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 1,066 | $10.48 | $11,171.68 |
DisclosureSEC source: 0001562180-22-007044 · primarydocument.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,457 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third quarter of 2022. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on October 3, 2022. F3 · balance_after: Includes 13,227 restricted stock units. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 18:31 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 245 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-22-000142 · wf-form4_166361228290829.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,197 F1 · shares: The equity acquired by the reporting person is the regular, annual grant of restricted stock units (pro-rated to reflect a partial year of service) provided by the Issuer to the reporting person pursuant to the Issuer's non-management director compensation package. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award. F2 · balance_after: Includes restricted stock units. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:07 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 164 | $16.79 | $2,753.56 |
DisclosureSEC source: 0001562180-22-005558 · primarydocument.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,391 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the second quarter of 2022. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on July 1, 2022. F3 · balance_after: Includes 13,227 restricted stock units. Read SEC document |
| June 06, 2022 Filed Jun 14, 2022 16:09 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (right to buy) · Derivative | 19,841 | $0.00 Strike: $16.67 | $0.00 |
DisclosureSEC source: 0001562180-22-005091 · primarydocument.xml · derivative · entry 2 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,841 Underlying: Common Stock · 19,841 shares Expires 2032-06-06 F3 · derivative.exercise_date: The option vests as to one-third of the shares on June 6, 2023, and the remaining two-thirds of the shares vest monthly thereafter over two years in 24 successive equal installments. Read SEC document |
| June 06, 2022 Filed Jun 14, 2022 16:09 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 13,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005091 · primarydocument.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,227 F1 · shares: Represents shares of stock issuable on vesting of restricted stock units. The restricted stock units vest as to one-third of shares on each of June 6, 2023, June 6, 2024 and June 6, 2025. F2 · balance_after: Includes 13,227 restricted stock units. Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 23:54 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 2,472 | $116.64 | $288,334.08 |
DisclosureSEC source: 0001596783-22-000014 · wf-form4_164194527924124.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,223 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to cover tax withholding obligations in connection with the vesting of restricted stock units received pursuant to the Issuer's long-term incentive plan. No shares were withheld by or surrendered to the Issuer. F2 · price: Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $116.61 to $116.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 20:26 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantOptions to purchase Common Stock · Derivative | 5,953 | $0.00 Strike: $113.00 | $0.00 |
DisclosureSEC source: 0001596783-21-000092 · wf-form4_162750398448061.xml · derivative · entry 2 Flynn Karen · CIK 0001553599 · Pres. Biologics & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,953 Underlying: Common Stock · 5,953 shares Expires 2031-07-26 F3 · shares: Received by the reporting person pursuant to the Issuer's annual grant to executive officers and other personnel under its long-term incentive plan. F4 · derivative.exercise_date: The options vest and become exercisable in four equal annual installments beginning on July 26, 2022. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 20:26 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 1,151 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-21-000092 · wf-form4_162750398448061.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Pres. Biologics & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,695 F1 · shares: Restricted stock units (RSUs) received by the reporting person pursuant to the Issuer's annual grant to executive officers and other personnel under its long-term incentive plan. Each RSU represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur three (3) years from the date of award. F2 · balance_after: Includes restricted stock units. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 00:12 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 1,100 | $112.50 | $123,750.00 |
DisclosureSEC source: 0001596783-21-000026 · wf-form4_161041033160277.xml · nonDerivative · entry 2 Flynn Karen · CIK 0001553599 · Pres. Biologics & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,544 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to cover tax withholding obligations in connection with the vesting of restricted stock units received pursuant to the Issuer's long-term incentive plan. No shares were withheld by or surrendered to the Issuer. F3 · balance_after: Includes restricted stock units. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 00:12 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 1,378 | $112.14 | $154,528.92 |
DisclosureSEC source: 0001596783-21-000026 · wf-form4_161041033160277.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Pres. Biologics & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,644 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to cover tax withholding obligations in connection with the vesting of restricted stock units received pursuant to the Issuer's long-term incentive plan. No shares were withheld by or surrendered to the Issuer. F2 · price: Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $111.44 to $112.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 02:44 UTC | Catalent, Inc. CTLT · Entity 16279 | SaleCommon Stock | 99 | $104.42 | $10,337.58 |
DisclosureSEC source: 0001596783-21-000014 · wf-form4_160990108479544.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Pres. Biologics & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,022 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to cover tax withholding obligations in connection with the vesting of restricted stock units received pursuant to the Issuer's long-term incentive plan. No shares were withheld by or surrendered to the Issuer. F2 · price: Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $104.30 to $104.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units. Read SEC document |
| July 30, 2020 Filed Aug 3, 2020 13:03 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantOptions to purchase Common Stock · Derivative | 8,005 | $0.00 Strike: $88.10 | $0.00 |
DisclosureSEC source: 0001596783-20-000105 · wf-form4_159645979824720.xml · derivative · entry 2 Flynn Karen · CIK 0001553599 · Pres. Biologics & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,005 Underlying: Common Stock · 8,005 shares Expires 2030-07-30 F3 · shares: Received by the reporting person pursuant to the Issuer's annual grant to executive officers and other personnel under its long-term incentive plan. F4 · derivative.exercise_date: The options vest and become exercisable in four equal annual installments beginning on July 30, 2021. Read SEC document |
| July 30, 2020 Filed Aug 3, 2020 13:03 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 1,476 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-20-000105 · wf-form4_159645979824720.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Pres. Biologics & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,121 F1 · shares: Restricted stock units (RSUs) received by the reporting person pursuant to the Issuer's annual grant to executive officers and other personnel under its long-term incentive plan. Each RSU represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur three (3) years from the date of award. F2 · balance_after: Includes restricted stock units. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 16:19 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 359 | $56.46 | $20,269.14 |
DisclosureSEC source: 0001596783-20-000037 · wf-form4_158679474913773.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Pres. Biologics & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,645 F1 · shares: Restricted stock units (RSUs) received in lieu of reporting person's receipt of certain other compensation. Each RSU represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur on December 31, 2020. F2 · balance_after: Includes restricted stock units. Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 16:22 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 35,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-20-000004 · wf-form4_157858691332565.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Pres. Biologics & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,286 F1 · shares: Restricted stock units (RSUs) received by the reporting person under the Issuer's omnibus incentive plan in connection with reporting person's election as an executive officer of Issuer. Each RSU represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur as to 25%, 25%, and 50% of the RSUs on each of the first three anniversaries of the grant date, respectively. F2 · balance_after: Includes restricted stock units. Read SEC document |
| December 05, 2019 Filed Dec 17, 2019 00:47 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantCommon Stock | 11,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000545 · edgar.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,283 F1 · shares: These restricted stock units will vest in full on the earlier of (i) a change of control of Recro Pharma, Inc. (the "Company") (as defined in the Company's 2018 Amended and Restated Equity Incentive Plan) or (ii) December 5, 2020, subject to continued service with the Company. Read SEC document |
| May 09, 2019 Filed May 13, 2019 14:43 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantStock Option (right to buy) · Derivative | 10,888 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001192482-19-000254 · edgar.xml · derivative · entry 2 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,888 Underlying: Common Stock · 10,888 shares Expires 2029-05-09 F2 · derivative.exercise_date: The stock option will vest on May 9, 2020. Read SEC document |
| May 09, 2019 Filed May 13, 2019 14:43 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantCommon Stock | 7,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000254 · edgar.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,212 F1 · shares: All shares of common stock are represented by unvested restricted stock units that will vest on May 9, 2020. Vested shares will be delivered to the reporting person within 30 days following the vesting date. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:12 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 14,280 | $102.51 Strike: $102.51 | $1,463,842.80 |
DisclosureSEC source: 0001562180-19-001219 · primarydocument.xml · derivative · entry 2 Flynn Karen · CIK 0001553599 · Sr VP & Chief Commercial Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,280 Underlying: Common Stock · 14,280 shares Expires 2029-02-19 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 19, 2020. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:12 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 2,099 | $102.51 | $215,168.49 |
DisclosureSEC source: 0001562180-19-001219 · primarydocument.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Sr VP & Chief Commercial Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,692.1476 F1 · shares: 2016 PSUs (PP15) award vesting. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 14:59 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 9,458 | $0.00 Strike: $21.22 | $0.00 |
DisclosureSEC source: 0001562180-18-003539 · primarydocument.xml · derivative · entry 5 Flynn Karen · CIK 0001553599 · Sr VP & Chief Commercial Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,458 shares Expires 2022-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 7/24/2013. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 14:59 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $25.15 | $0.00 |
DisclosureSEC source: 0001562180-18-003539 · primarydocument.xml · derivative · entry 4 Flynn Karen · CIK 0001553599 · Sr VP & Chief Commercial Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,982 Underlying: Common Stock · 11,000 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/21/2013. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 14:59 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 20,458 | $116.23 | $2,377,833.34 |
DisclosureSEC source: 0001562180-18-003539 · primarydocument.xml · nonDerivative · entry 3 Flynn Karen · CIK 0001553599 · Sr VP & Chief Commercial Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,593.1476 F1 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $116.00 to $116.635 inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 14:59 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 11,000 | $25.15 | $276,595.00 |
DisclosureSEC source: 0001562180-18-003539 · primarydocument.xml · nonDerivative · entry 2 Flynn Karen · CIK 0001553599 · Sr VP & Chief Commercial Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,051.1476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 14:59 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 9,458 | $21.22 | $200,698.76 |
DisclosureSEC source: 0001562180-18-003539 · primarydocument.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Sr VP & Chief Commercial Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,051.1476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2018 Filed May 14, 2018 20:55 UTC | Societal CDMO, Inc. REPH · Entity 92137 | Exercise / conversionRestricted Stock Units · Derivative | 13,274 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-18-000208 · edgar.xml · derivative · entry 2 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,274 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On May 12, 2017, the reporting person was granted 13,274 restricted stock units, vesting on the first anniversary of the grant date. F2 · derivative.expiration_date: On May 12, 2017, the reporting person was granted 13,274 restricted stock units, vesting on the first anniversary of the grant date. Read SEC document |
| May 12, 2018 Filed May 14, 2018 20:55 UTC | Societal CDMO, Inc. REPH · Entity 92137 | Exercise / conversionCommon Stock | 13,274 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-18-000208 · edgar.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:25 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantStock Option (right to buy) · Derivative | 5,742 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001192482-18-000182 · edgar.xml · derivative · entry 2 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,742 Underlying: Common Stock · 5,742 shares Expires 2028-05-04 F2 · derivative.exercise_date: The stock option will vest on May 4, 2019. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:25 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantCommon Stock | 6,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-18-000182 · edgar.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,983 F1 · shares: All shares of common stock are represented by unvested restricted stock units that will vest on May 4, 2019. Vested shares will be delivered to the reporting person within 30 days following the vesting date. Read SEC document |
| May 04, 2018 Filed May 10, 2018 22:54 UTC Amendment | Societal CDMO, Inc. REPH · Entity 92137 | GrantStock Option (right to buy) · Derivative | 8,965 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001192482-18-000193 · edgar.xml · derivative · entry 1 Flynn Karen · CIK 0001553599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,965 Underlying: Common Stock · 8,965 shares Expires 2028-05-04 F1 · shares: This amended Form 4 is being filed to correct a typographical error in the number of stock options acquired on May 4, 2018 as reported on the Form 4 filed on May 8, 2018. F2 · derivative.exercise_date: The stock option will vest on May 4, 2019. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 22:43 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 17,544 | $89.64 Strike: $89.64 | $1,572,644.16 |
DisclosureSEC source: 0001562180-18-001152 · primarydocument.xml · derivative · entry 1 Flynn Karen · CIK 0001553599 · Sr VP & Chief Commercial Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,544 Underlying: Common Stock · 17,544 shares Expires 2028-02-20 F1 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/20/2019 Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 23:29 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 3,870 | $93.00 | $359,910.00 |
DisclosureSEC source: 0001562180-18-001013 · primarydocument.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Sr VP & Chief Commercial Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,593.1476 F1 · shares: 2015 PSU (PP14) award vesting Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 22:56 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 7.484 | $98.67 | $738.45 |
DisclosureSEC source: 0001562180-18-000149 · primarydocument.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Sr VP & Chief Commercial Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,723.1476 Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 23:08 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 7.4509 | $99.11 | $738.46 |
DisclosureSEC source: 0001562180-17-003744 · primarydocument.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Sr VP & Chief Commercial Offic 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 1,297.5031 Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 21:07 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 7.4622 | $98.96 | $738.46 |
DisclosureSEC source: 0001562180-17-003649 · primarydocument.xml · nonDerivative · entry 1 Flynn Karen · CIK 0001553599 · Sr VP & Chief Commercial Offic 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 1,290.0522 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.